

EDGAR Submission Header Summary	
Submission Form Type	6-K
XBRL	NonXBRLSubmission
Period of Report	11-17-2021
Filer	Nanobiotix S.A.
CIK	0001760854
CCC	xxxxxxx
Exchanges	NASD
Co-Registrants	
Submission Contact	
Contact Phone Number	
Documents	2

Documents	
6-K	a52533049.htm
Description	Nanobiotix S.A. 6-K
EX-99.1	a52533049ex99_1.htm
Description	Exhibit 99.1

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 6-K

**Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934**

Date of Report: 11/17/2021

Commission File Number: 001-39777

Nanobiotix S.A.
(Exact Name of Registrant as Specified in its Charter)

**60 Rue de Wattignies
75012 Paris, France**
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

EXHIBIT INDEX

Exhibit **Title**

[99.1](#) [Press Release, dated November 17, 2021](#)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

PORTER NOVELLI
(Agency)

By: /s/ Emily Papp
Emily Papp
Senior Account Executive

NANOBIOTIX S.A.
(Registrant)

By: /s/ Bart Van Rhijn
Bart Van Rhijn
Chief Financial Officer

NANOBIOTIX to Present at the 4th Annual Evercore ISI HealthCONx Conference

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--November 17, 2021--Regulatory News:

NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the “**Company**”) (Paris:NANO) (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that Laurent Levy, co-founder and chief executive officer, will participate in a virtual fireside chat at the 4th annual Evercore ISI HealthCONx Conference on Thursday, December 2, 2021, at 1:00 PM EST / 7:00 PM CET .

A link to the live audio webcast will be available on the Events section of the company’s website at www.nanobiotix.com. An archived recording of the presentation will be available for 90 days.

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France. The company also has subsidiaries in Cambridge, Massachusetts (United States), France, Spain, and Germany. Nanobiotix has been listed on the regulated market of Euronext in Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020.

Nanobiotix is the owner of more than 30 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system. The company's resources are primarily devoted to the development of its lead product candidate– NBTXR3 —which is the product of its proprietary oncology platform and has already achieved market authorization in Europe for the treatment of patients with soft tissue sarcoma under the brand name Hensify®.

For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.

Contacts

Nanobiotix

Communications Department

Brandon Owens
VP, Communications
 +1 (617) 852-4835
contact@nanobiotix.com

Investor Relations Department

Kate McNeil
SVP, Investor Relations
 +1 (609) 678-7388
investors@nanobiotix.com

Media Relations

France – Ulysse Communication

Pierre-Louis Germain
 + 33 (0) 6 64 79 97 51
plgermain@ulyse-communication.com

US – Porter Novelli

Dan Childs
 +1 (781) 888-5106
Dan.childs@porternovelli.com